Top

CardioVascular and Interventional Radiology

Published in:

01-07-2007 | Laboratory Investigation

Improved Patency of Transjugular Intrahepatic Portosystemic Shunt: The Efficacy of Cilostazol for the Prevention of Pseudointimal Hyperplasia in Swine TIPS Models

Authors: Sang Woo Park, In Ho Cha, Chul Hwan Kim, Hae Jeong Jeon, Jeong Hee Park, Suk Joo Hong, In Sik Lee

Published in: CardioVascular and Interventional Radiology | Issue 4/2007

Abstract

Purpose

To investigate the efficacy of oral administration of cilostazol to inhibit pseudointimal/intimal hyperplasia in swine TIPS models.

Methods

Successful TIPS creation was carried out in 11 of 12 healthy young pigs (20–25 kg). In the treatment group (n = 6), both cilostazol and aspirin were administered daily, from the first day of TIPS creation. The control group (n = 5) was administered only aspirin. The animals were followed-up for 2 weeks and then killed. The specimen (including portal vein, hepatic parenchymal tract, hepatic vein, and inferior vena cava) and stents were carefully bisected in a longitudinal fashion. The control group was compared with the treatment group by means of a gross and histologic evaluation of the degree of pseudointimal/intimal hyperplasia in the shunt.

Results

At the gross evaluation, the control group showed considerably more pseudointimal/intimal hyperplasia than the treatment group. Using microscopic evaluation, there was a statistically significant difference (p < 0.05) in the mean maximum pseudointimal/intimal hyperplasia thickness between the control group (2.97 ± 0.33 mm) and treatment group (0.73 ± 0.27 mm).

Conclusion

Oral administration of cilostazol may have been effective in reducing pseudointimal/intimal hyperplasia in swine TIPS models.

Laberge JM, Somberg KA, Lake JR, et al. (1995) Two year outcome following transjugular intrahepatic portosystemic stent-shunt for variceal bleeding: Results in 90 patients. Gastroenterology 108:1143–1151PubMedCrossRef

Luca A, D’Amico G, La Galla R, Midiri M, Morabito A, Pagliaro L (1999) TIPS for prevention of recurrent bleeding in patients with cirrhosis: Meta-analysis of randomized clinical trials. Radiology 212:411–421PubMed

Papatheodoridis GV, Goulis J, Leandro G, Patch D, Burroughs AK (1999) Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis. Hepatology 30:612–622PubMedCrossRef

Rossle M, Sieterstetter V, Huber M, Ochs A (1998) The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): State of the art. Liver 19:73–89

Bilbao JI, Quroga J, Herrero JI, Benito A (2002) Transjugular intrahepatic portosystemic shunt (TIPS): Current status and future possibilities. Cardiovasc Intervent Radiol 25:251–269PubMedCrossRef

Nishimine K, Saxon RR, Kichikawa K, et al. (1995) Improved transjugular intrahepatic portosystemic shunt patency with PTFE-covered stent-grafts: Experimental results in swine. Radiology 196:341–347PubMed

Tanihata H, Saxon RR, Kubota R, et al. (1997) Transjugular intrahepatic portosystemic shunt with silicone-covered Wallstents: Results in a swine model. Radiology 205:181–184PubMed

Haskal ZJ (1999) Improved patency of transjugular intrahepatic portosystemic shunts in humans: Creation and revision with PTFE stent-grafts. Radiology 213:759–766PubMed

Haskal ZJ, Davis A, McAllister A, Furth EE (1997) PTFE-encapsulated endovascular stent-graft for transjugular intrahepatic portosystemic shunt: Experimental evaluation. Radiology 205:682–688PubMed

10.

Otal P, Smayra T, Bureau C, et al. (2002) Preliminary results of a new expanded-polytetrafluoroethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt procedures. AJR Am J Roentgenol 178:141–147PubMed

11.

Hausegger KA, Karnel F, Georgieva B, et al. (2004) Transjugular intrahepatic portosystemic shunt creation with the Viatorr expanded polytetrafluoroethylene-covered stent-graft. J Vasc Interv Radiol 15:239–248PubMed

12.

Tsuchikane E, et al. (1999) Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 100:21–26PubMed

13.

Umekawa H, Tanaka T, Kimura Y, Hidaka H (1984) Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography. Biochem Pharmacol 33:3339–3344PubMedCrossRef

14.

Tanaka T, Ishikawa T, Hagiwara M, et al. (1988) Effect of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 36:313–320PubMedCrossRef

15.

Takahashi S, Oida K, Fujiwara R, et al. (1992) Effect of cilostazol, a cycle AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cell in culture. J Cardiovasc Pharmacol 20:900–906PubMedCrossRef

16.

Kubota Y, Kichikawa K, Uchida H, et al. (1995) Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. Invest Radiol 30:532–537PubMedCrossRef

17.

Kamishirado H, Inoue T, Mizoguchi K, et al. (2002) Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. Am Heart J 144:303–308PubMed

18.

Zhuang ZW, Hoopes PJ, Koutras PC, et al. (2001) Transjugular intrahepatic portosystemic shunt with an autologous vein-covered stent: Results in a swine model. J Vasc Interv Radiol 12:1333–1342PubMedCrossRef

19.

Teng GJ, Betmann MA, Hoopes PJ, Ermeling BL, et al. (1998) Transjugular jugular intrahepatic portosystemic shunt in a porcine model: Histological characteristics a the early stage. Acad Radiol 5:547–555PubMedCrossRef

20.

Nazarian GK, Ferral H, Castaneda-Zuniga WR, et al. (1994) Development of stenoses in transjugular intrahepatic portosystemic shunts. Radiology 192:231–234PubMed

21.

Haskal ZJ, Pentecost MJ, Soulen MC, et al. (1994) Transjugular intrahepatic portosystemic shunt stenosis and revision: Early and midterm results. AJR Am J Roentgenol 163:439–444PubMed

22.

Teng GJ, Bettmann MA, Hoopes PJ, et al. (1998) Transjugular intrahepatic portosystemic shunt: effect of bile leak on smooth muscle cell proliferation. Radiology 208:799–805PubMed

23.

Stout LC, Lyon RE, Murray GB, Barth MH (1995) Pseudointimal biliary epithelial proliferation and Azhn’s infarct associated with 61/2-month old transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 90:126–130PubMed

24.

Siegerstetter V, Huber M, Ochs A, Blum HE, Rossle M (1999) Platelet aggregation and platelet-derived growth factor inhibition for prevention of insufficiency of the transjugular intrahepatic portosystemic shunt: A randomized study comparing trapidil plus ticlopidine with heparin treatment. Hepatology 29:33–38PubMedCrossRef

25.

Okuda Y, Kimura Y, Yamashita K (1993) Cilostazol. Cardiovasc Drug Rev 11:451–465CrossRef

26.

Mishima Y, Tanabe T, Yasuda K (1986) Clinical evaluation of OPC-13013, a new platelet aggregation inhibitor, on chronic arterial occlusive diseases: Dose finding study by double-blind method. Clin Eval 14:13–41

27.

Law MM, Colburn MD, Hajjar GE, et al. (1994) Suppression of intimal hyperplasia in a rabbit model of arterial balloon injury by enalaprilat but not dimethylsulfoxide. Ann Vasc Surg 8:158–165PubMedCrossRef

28.

Matsumoto Y, Tani T, Watanabe K, Kimura Y (1992) Effects of cilostazol, an antiplatelet drug, on smooth muscle cell proliferation after endothelial denudation in rats. Jpn J Pharmacol 58:284

29.

Sounces JE, Hassall GA, Parrott DP (1992) Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem Pharmacol 44:857–866CrossRef

30.

Marx J (1993) Two major signal pathways linked. Science 262:988–900PubMedCrossRef

Title: Improved Patency of Transjugular Intrahepatic Portosystemic Shunt: The Efficacy of Cilostazol for the Prevention of Pseudointimal Hyperplasia in Swine TIPS Models
Authors: Sang Woo Park
In Ho Cha
Chul Hwan Kim
Hae Jeong Jeon
Jeong Hee Park
Suk Joo Hong
In Sik Lee
Publication date: 01-07-2007
Publisher: Springer-Verlag
Published in: CardioVascular and Interventional Radiology / Issue 4/2007
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-007-9001-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Improved Patency of Transjugular Intrahepatic Portosystemic Shunt: The Efficacy of Cilostazol for the Prevention of Pseudointimal Hyperplasia in Swine TIPS Models

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2007

Endovascular Repair of Localized Pathological Lesions of the Descending Thoracic Aorta: Midterm Results

Percutaneous Management of Complications (Aortoenteric Fistula and Sac Abscess) Following Bypass Surgery for Abdominal Aortic Aneurysm

Embolization of a Giant Hepatic Hemangioma Prior To Urgent Liver Resection. Case Report and Review of the Literature

Interventional Radiological Management of Prehepatic Obstruction the Splanchnic Venous System

Chest Wall Dissemination of Nocardiosis after Percutaneous Transthoracic Needle Biopsy

Aorto-iliac Endovascular Reconstruction by Kissing Stenting Through Bilateral Brachial Access